Infinity drugs gets orphan status
September 17, 2007 10:12 AM
E-mail|
|Comments
()|
Text size
–
+
Infinity Pharmaceuticals Inc. said today that the Food and Drug Administration granted its cancer treatment candidate IPI-504 orphan drug status.
That designation gives companies seven years of market exclusivity with the drug along with reduced application fees, if the drug is approved.
The drug is aimed at treating a range of cancers and was given the special status specifically for use as a treatment for gastrointestinal stromal tumors. It is being developed with MedImmune, now part of AstraZeneca PLC. (AP)
Comment
Permalink
E-mail
